Ads
related to: belimumab for lupus nephritis- BENLYSTA Dosing Options
Consider Her Schedule And Needs.
Discover The Option That Fits Her.
- What About BENLYSTA?
Could BENLYSTA Be Another Option?
See the Data, Dosing & Resources.
- BENLYSTA Safety Profile
What Your Patients May Experience.
Learn About Possible Side Effects.
- BENLYSTA Resource Center
Discover A Library Of Resources
Designed To Inform You. Learn More.
- BENLYSTA Video Library
See Video Stories From Peers &
Dig Into BENLYSTA Patient Profiles.
- Learn More About BENLYSTA
Learn More About BENLYSTA & See
If It's An Option For Your Patient.
- BENLYSTA Dosing Options
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
Childhood-onset systemic lupus erythematosus (i.e., cSLE), also termed juvenile-onset systemic lupus erythematosus, juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, is a form of the chronic inflammatory and autoimmune disease, systemic lupus erythematosus (i.e., SLE), that develops in individuals up to 18 years old. [1]
Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases.
For premium support please call: 800-290-4726 more ways to reach us
Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus ...
Lupus nephritis commonly leads patients to chronic kidney failure and therefore places an emphasis on early intervention for improving treatment outcomes. It is a significant risk factor for morbidity and mortality in systemic lupus erythematosus. The management of lupus nephritis comprises immunosuppressive therapy to lessen inflammation and ...
Ads
related to: belimumab for lupus nephritis